<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01010282</url>
  </required_header>
  <id_info>
    <org_study_id>AG9965-002</org_study_id>
    <nct_id>NCT01010282</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, efficacy, and acceptability of two artificial tears
      compared to a currently available artificial tear in subjects with dry eye.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Subjective Evaluation of Symptom of Dryness (SESoD)Score at Day 90</measure>
    <time_frame>Baseline (Day 1), Day 90</time_frame>
    <description>Change from baseline in SESoD score at day 90. The SESoD is a 5-point scale where 0 equals no dryness, 1 equals trace dryness, 2 equals mild dryness, 3 equals moderate dryness, and 4 equals severe dryness. A negative number change from baseline indicates a decrease (improvement) in the symptom of dryness.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Ocular Surface Disease Index (OSDI) Total Score at Day 90</measure>
    <time_frame>Baseline (Day 1), Day 90</time_frame>
    <description>Change from baseline in the OSDI total score at day 90. The OSDI is a 12-question survey for patients to document their dry eye disease symptoms. The OSDI consists of a 5-point scale (0=none of the time and 4=all of the time), with higher scores representing greater disability. The scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tear Break-up Time (TBUT) at Day 90</measure>
    <time_frame>Baseline (Day 1), Day 90</time_frame>
    <description>Change from baseline in TBUT at day 90. TBUT is the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A positive number change from baseline indicates an increase in TBUT (improvement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Corneal Staining at Day 90</measure>
    <time_frame>Baseline (Day 1), Day 90</time_frame>
    <description>Change from baseline in corneal staining at day 90. The cornea is the transparent front part of the eye which covers the iris and pupil. Corneal staining following administration of fluorescein dye in the eye is graded using a 6-point scale (0=no staining, 5=severe staining) over 5 areas of the clear central part of the eye for a minimum score of 0 and maximum score of 25. The higher the grade score, the worse the dry eye condition. A negative number change from baseline represents a decrease in corneal staining (improvement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Conjunctival Staining Severity Score at Day 90</measure>
    <time_frame>Baseline (Day 1), Day 90</time_frame>
    <description>Change from baseline in conjunctival staining severity score at day 90. The conjunctiva is the clear membrane covering the white surface of the eye. Conjunctival staining following ocular administration of lissamine green dye was graded using a 6-point scale (0=no staining, 5=severe staining) over 6 areas of the white part of the eye for a minimum score of 0 and a maximum score of 30. The higher the score, the worse the dry eye condition. A negative number change from baseline represents a decrease in the severity of conjunctival staining (improvement).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">288</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>Glycerin and Polysorbate 80 based artificial tear</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glycerin and Polysorbate 80 based artificial tear</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Artificial Tears Formulation 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Artificial Tears Formulation 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycerin and Polysorbate 80 based artificial tear</intervention_name>
    <description>1-2 drops in each eye, as needed, but at least twice daily</description>
    <arm_group_label>Glycerin and Polysorbate 80 based artificial tear</arm_group_label>
    <other_name>Refresh Dry Eye Therapy® Lubricant Eye Drops</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear</intervention_name>
    <description>1-2 drops in each eye, as needed, but at least twice daily</description>
    <arm_group_label>Artificial Tears Formulation 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear</intervention_name>
    <description>1-2 drops in each eye, as needed, but at least twice daily</description>
    <arm_group_label>Artificial Tears Formulation 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current use of an artificial tear at least twice daily, for at least three months
             prior to Day 1, on average

          -  Ability/agreement to wear habitual correction (glasses) during study period

        Exclusion Criteria:

          -  Known allergy or sensitivity to the study product(s) or its components

          -  Anticipate contact lens wear during the study, or subject has worn contact lenses in
             the last six months

          -  Chronic use of systemic medications which may affect a dry eye condition

          -  Active ocular allergy or infection

          -  Use of Restasis® or other topical cyclosporine products within 3 months prior to Day 1

          -  Current use of any topical ophthalmic medications, have used within 2 weeks prior to
             Day 1, or are likely to use during study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2009</study_first_submitted>
  <study_first_submitted_qc>November 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2009</study_first_posted>
  <results_first_submitted>November 9, 2011</results_first_submitted>
  <results_first_submitted_qc>November 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 13, 2011</results_first_posted>
  <last_update_submitted>July 22, 2015</last_update_submitted>
  <last_update_submitted_qc>July 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycerol</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Artificial Tears Formulation 1</title>
          <description>Artificial Tears Formulation 1</description>
        </group>
        <group group_id="P2">
          <title>Artificial Tears Formulation 2</title>
          <description>Artificial Tears Formulation 2</description>
        </group>
        <group group_id="P3">
          <title>Glycerin and Polysorbate 80 Based Artificial Tear</title>
          <description>Glycerin and Polysorbate 80 based artificial tear</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="95"/>
                <participants group_id="P3" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Artificial Tears Formulation 1</title>
          <description>Artificial Tears Formulation 1</description>
        </group>
        <group group_id="B2">
          <title>Artificial Tears Formulation 2</title>
          <description>Artificial Tears Formulation 2</description>
        </group>
        <group group_id="B3">
          <title>Glycerin and Polysorbate 80 Based Artificial Tear</title>
          <description>Glycerin and Polysorbate 80 based artificial tear</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="97"/>
            <count group_id="B2" value="95"/>
            <count group_id="B3" value="96"/>
            <count group_id="B4" value="288"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>between 30 and 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Subjective Evaluation of Symptom of Dryness (SESoD)Score at Day 90</title>
        <description>Change from baseline in SESoD score at day 90. The SESoD is a 5-point scale where 0 equals no dryness, 1 equals trace dryness, 2 equals mild dryness, 3 equals moderate dryness, and 4 equals severe dryness. A negative number change from baseline indicates a decrease (improvement) in the symptom of dryness.</description>
        <time_frame>Baseline (Day 1), Day 90</time_frame>
        <population>Intent-to-treat, which includes all patients who started the study (randomized).</population>
        <group_list>
          <group group_id="O1">
            <title>Artificial Tears Formulation 1</title>
            <description>Artificial Tears Formulation 1</description>
          </group>
          <group group_id="O2">
            <title>Artificial Tears Formulation 2</title>
            <description>Artificial Tears Formulation 2</description>
          </group>
          <group group_id="O3">
            <title>Glycerin and Polysorbate 80 Based Artificial Tear</title>
            <description>Glycerin and Polysorbate 80 based artificial tear</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Subjective Evaluation of Symptom of Dryness (SESoD)Score at Day 90</title>
          <description>Change from baseline in SESoD score at day 90. The SESoD is a 5-point scale where 0 equals no dryness, 1 equals trace dryness, 2 equals mild dryness, 3 equals moderate dryness, and 4 equals severe dryness. A negative number change from baseline indicates a decrease (improvement) in the symptom of dryness.</description>
          <population>Intent-to-treat, which includes all patients who started the study (randomized).</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.59"/>
                    <measurement group_id="O2" value="2.8" spread="0.67"/>
                    <measurement group_id="O3" value="2.8" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.89"/>
                    <measurement group_id="O2" value="-0.7" spread="0.90"/>
                    <measurement group_id="O3" value="-0.7" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Ocular Surface Disease Index (OSDI) Total Score at Day 90</title>
        <description>Change from baseline in the OSDI total score at day 90. The OSDI is a 12-question survey for patients to document their dry eye disease symptoms. The OSDI consists of a 5-point scale (0=none of the time and 4=all of the time), with higher scores representing greater disability. The scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement.</description>
        <time_frame>Baseline (Day 1), Day 90</time_frame>
        <population>Intent-to-treat, which includes all patients who started the study (randomized).</population>
        <group_list>
          <group group_id="O1">
            <title>Artificial Tears Formulation 1</title>
            <description>Artificial Tears Formulation 1</description>
          </group>
          <group group_id="O2">
            <title>Artificial Tears Formulation 2</title>
            <description>Artificial Tears Formulation 2</description>
          </group>
          <group group_id="O3">
            <title>Glycerin and Polysorbate 80 Based Artificial Tear</title>
            <description>Glycerin and Polysorbate 80 based artificial tear</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Ocular Surface Disease Index (OSDI) Total Score at Day 90</title>
          <description>Change from baseline in the OSDI total score at day 90. The OSDI is a 12-question survey for patients to document their dry eye disease symptoms. The OSDI consists of a 5-point scale (0=none of the time and 4=all of the time), with higher scores representing greater disability. The scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement.</description>
          <population>Intent-to-treat, which includes all patients who started the study (randomized).</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" spread="20.19"/>
                    <measurement group_id="O2" value="35.1" spread="19.18"/>
                    <measurement group_id="O3" value="37.3" spread="18.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" spread="19.47"/>
                    <measurement group_id="O2" value="-10.6" spread="18.43"/>
                    <measurement group_id="O3" value="-9.1" spread="19.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Tear Break-up Time (TBUT) at Day 90</title>
        <description>Change from baseline in TBUT at day 90. TBUT is the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A positive number change from baseline indicates an increase in TBUT (improvement).</description>
        <time_frame>Baseline (Day 1), Day 90</time_frame>
        <population>Intent-to-treat, which includes all patients who started the study (randomized).</population>
        <group_list>
          <group group_id="O1">
            <title>Artificial Tears Formulation 1</title>
            <description>Artificial Tears Formulation 1</description>
          </group>
          <group group_id="O2">
            <title>Artificial Tears Formulation 2</title>
            <description>Artificial Tears Formulation 2</description>
          </group>
          <group group_id="O3">
            <title>Glycerin and Polysorbate 80 Based Artificial Tear</title>
            <description>Glycerin and Polysorbate 80 based artificial tear</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tear Break-up Time (TBUT) at Day 90</title>
          <description>Change from baseline in TBUT at day 90. TBUT is the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A positive number change from baseline indicates an increase in TBUT (improvement).</description>
          <population>Intent-to-treat, which includes all patients who started the study (randomized).</population>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.90" spread="1.768"/>
                    <measurement group_id="O2" value="5.04" spread="1.653"/>
                    <measurement group_id="O3" value="5.09" spread="1.782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="2.955"/>
                    <measurement group_id="O2" value="2.02" spread="3.812"/>
                    <measurement group_id="O3" value="1.81" spread="3.464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Corneal Staining at Day 90</title>
        <description>Change from baseline in corneal staining at day 90. The cornea is the transparent front part of the eye which covers the iris and pupil. Corneal staining following administration of fluorescein dye in the eye is graded using a 6-point scale (0=no staining, 5=severe staining) over 5 areas of the clear central part of the eye for a minimum score of 0 and maximum score of 25. The higher the grade score, the worse the dry eye condition. A negative number change from baseline represents a decrease in corneal staining (improvement).</description>
        <time_frame>Baseline (Day 1), Day 90</time_frame>
        <population>Intent-to-treat, which includes all patients who started the study (randomized).</population>
        <group_list>
          <group group_id="O1">
            <title>Artificial Tears Formulation 1</title>
            <description>Artificial Tears Formulation 1</description>
          </group>
          <group group_id="O2">
            <title>Artificial Tears Formulation 2</title>
            <description>Artificial Tears Formulation 2</description>
          </group>
          <group group_id="O3">
            <title>Glycerin and Polysorbate 80 Based Artificial Tear</title>
            <description>Glycerin and Polysorbate 80 based artificial tear</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Corneal Staining at Day 90</title>
          <description>Change from baseline in corneal staining at day 90. The cornea is the transparent front part of the eye which covers the iris and pupil. Corneal staining following administration of fluorescein dye in the eye is graded using a 6-point scale (0=no staining, 5=severe staining) over 5 areas of the clear central part of the eye for a minimum score of 0 and maximum score of 25. The higher the grade score, the worse the dry eye condition. A negative number change from baseline represents a decrease in corneal staining (improvement).</description>
          <population>Intent-to-treat, which includes all patients who started the study (randomized).</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="3.14"/>
                    <measurement group_id="O2" value="4.2" spread="2.91"/>
                    <measurement group_id="O3" value="4.5" spread="3.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="3.35"/>
                    <measurement group_id="O2" value="-0.5" spread="3.01"/>
                    <measurement group_id="O3" value="0.8" spread="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Conjunctival Staining Severity Score at Day 90</title>
        <description>Change from baseline in conjunctival staining severity score at day 90. The conjunctiva is the clear membrane covering the white surface of the eye. Conjunctival staining following ocular administration of lissamine green dye was graded using a 6-point scale (0=no staining, 5=severe staining) over 6 areas of the white part of the eye for a minimum score of 0 and a maximum score of 30. The higher the score, the worse the dry eye condition. A negative number change from baseline represents a decrease in the severity of conjunctival staining (improvement).</description>
        <time_frame>Baseline (Day 1), Day 90</time_frame>
        <population>Intent-to-treat, which includes all patients who started the study (randomized).</population>
        <group_list>
          <group group_id="O1">
            <title>Artificial Tears Formulation 1</title>
            <description>Artificial Tears Formulation 1</description>
          </group>
          <group group_id="O2">
            <title>Artificial Tears Formulation 2</title>
            <description>Artificial Tears Formulation 2</description>
          </group>
          <group group_id="O3">
            <title>Glycerin and Polysorbate 80 Based Artificial Tear</title>
            <description>Glycerin and Polysorbate 80 based artificial tear</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Conjunctival Staining Severity Score at Day 90</title>
          <description>Change from baseline in conjunctival staining severity score at day 90. The conjunctiva is the clear membrane covering the white surface of the eye. Conjunctival staining following ocular administration of lissamine green dye was graded using a 6-point scale (0=no staining, 5=severe staining) over 6 areas of the white part of the eye for a minimum score of 0 and a maximum score of 30. The higher the score, the worse the dry eye condition. A negative number change from baseline represents a decrease in the severity of conjunctival staining (improvement).</description>
          <population>Intent-to-treat, which includes all patients who started the study (randomized).</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="4.71"/>
                    <measurement group_id="O2" value="4.9" spread="4.37"/>
                    <measurement group_id="O3" value="5.2" spread="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="4.17"/>
                    <measurement group_id="O2" value="-0.7" spread="4.53"/>
                    <measurement group_id="O3" value="-0.7" spread="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Artificial Tears Formulation 1</title>
          <description>Artificial Tears Formulation 1</description>
        </group>
        <group group_id="E2">
          <title>Artificial Tears Formulation 2</title>
          <description>Artificial Tears Formulation 2</description>
        </group>
        <group group_id="E3">
          <title>Glycerin and Polysorbate 80 Based Artificial Tear</title>
          <description>Glycerin and Polysorbate 80 based artificial tear</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Allergan, Inc.</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

